Perrigo reported $436.6M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
AbbVie USD 10.77B 4.2B Sep/2026
Abbott USD 4.05B 1.05B Sep/2026
Bayer EUR 4.29B 1.44B Jun/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Corcept Therapeutics USD 98.72M 12.32M Sep/2026
Dr.Reddys Laboratories INR 11.2B 4.16B Jun/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Merck USD 9.55B 2.7B Sep/2026
Nestle CHF 3.55B 1.03B Jun/2026
Perrigo USD 436.6M 36.9M Sep/2026
Pfizer USD 1.82B 848M Sep/2026
Phibro Animal Health USD 75.55M 14.13M Sep/2026
Prestige Brands USD 46.52M 42.61M Sep/2026
Reckitt Benckiser GBP 880M 106M Dec/2024
Sanofi EUR 6.35B 806M Jun/2026
Supernus Pharmaceuticals USD 175.88M 4.07M Sep/2026
Teva Pharmaceutical Industries USD 4.08B 430M Sep/2026
Xeris Pharmaceuticals USD 131.08M 9.33M Sep/2026
Zoetis USD 1.33B 143M Sep/2026